Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Emilie Le Rhun, Sophie Taillibert, Marc C Chamberlain, Emilie Le Rhun, Sophie Taillibert, Marc C Chamberlain

Abstract

Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the leptomeninges, giving rise to central nervous system dysfunction. Breast cancer, lung cancer, and melanoma are the most frequent causes of LM among solid tumors in adults. An early diagnosis of LM, before fixed neurologic deficits are manifest, permits earlier and potentially more effective treatment, thus leading to a better quality of life in patients so affected. Apart from a clinical suspicion of LM, diagnosis is dependent upon demonstration of cancer in cerebrospinal fluid (CSF) or radiographic manifestations as revealed by neuraxis imaging. Potentially of use, though not commonly employed, today are use of biomarkers and protein profiling in the CSF. Symptomatic treatment is directed at pain including headache, nausea, and vomiting, whereas more specific LM-directed therapies include intra-CSF chemotherapy, systemic chemotherapy, and site-specific radiotherapy. A special emphasis in the review discusses novel agents including targeted therapies, that may be promising in the future management of LM. These new therapies include anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib in nonsmall cell lung cancer, anti-HER2 monoclonal antibody trastuzumab in breast cancer, anti-CTLA4 ipilimumab and anti-BRAF tyrosine kinase inhibitors such as vermurafenib in melanoma, and the antivascular endothelial growth factor monoclonal antibody bevacizumab are currently under investigation in patients with LM. Challenges of managing patients with LM are manifold and include determining the appropriate patients for treatment as well as the optimal route of administration of intra-CSF drug therapy.

Keywords: Diagnostic tools; leptomeningeal metastases; monoclonal antibody; neoplastic meningitis; solid tumors; targeted therapy; tyrosine kinase inhibitors.

References

    1. Adamson PC, Balis FM, Arndt CA, Holcenberg JS, Narang PK, Murphy RF, et al. Intrathecal 6-mercap- topurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Res. 1991;51:6079–83.
    1. Agarwal A, Vijay K, Thamburaj K, Ouyang T. Transient leukoencephalopathy after intrathecal methotrexate mimicking stroke. Emerg Radiol. 2011;18:345–7.
    1. Ahn JH, Lee SH, Kim S, Joo J, Yoo H, Lee SH, et al. Risk for leptomeningeal seeding after resection for brain metastases: Implication of tumor location with mode of resection. J Neurosurg. 2012;116:984–93.
    1. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.
    1. Aradillas E, Arora R, Gasperino J. Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther. 2011;36:529–36.
    1. Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, et al. Regional treatment of epidermal growth factor receptor vIII- expressing neoplastic meningitis with a single-chain immunotoxin, MR-I. Clin Cancer Res. 1999;5:2646–52.
    1. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol. 1989;11:74–86.
    1. Balm M, Hammack J. Leptomeningeal carcinomatosis: Presenting features and prognostic factors. Arch Neurol. 1996;53:626–32.
    1. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–7.
    1. Benjamin JC, Moss T, Moseley RP, Maxwell R, Coakham HB. Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody. Neurosurgery. 1989;25:253–8.
    1. Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol. 1992;10:143–8.
    1. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269–78.
    1. Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, et al. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin Cancer Res. 1995;1:1545–55.
    1. Blaney S, Balis F, Murphy RF, Arndt CA, Gillepsie A, Poplack DG. A phase I study of intrathecal mafosfamide (MF) in patients with refractory meningeal malignancies, Abstract 274. Am Soc Clin Oncol. 1992;11:113.
    1. Blaney S, Poplack D, Godwin K, McCully C, Murphy RF, Balis F. The effect of body position on ventricular cerebrospinal fluid methotrexate following intralumbar administration. J Clin Oncol. 1995;13:177–9.
    1. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003;21:143–7.
    1. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975;195:73–83.
    1. Bleyer WA, Drake J, Chabner B. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973;289:770–3.
    1. Bleyer WA, Poplack DG, Simon RM. “Concentration-time” methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978;51:835–42.
    1. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases in solid tumors: Exclusion of intra-CSF chemotherapy does not affect treatment outcome. Comparison of two prospective series. Neurology. 1997;48:A35.
    1. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.
    1. Boogerd W, vd Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry. 1988;51:1277–83.
    1. Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer. 1991;67:1685–95.
    1. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;55:117–9.
    1. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: A randomised study. Eur J Cancer. 2004;40:2726–33.
    1. Bot I, Blank CD, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol. 2012;259:1976–8.
    1. Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumour: A clinical and pathological study of 63 cases. Postgrad Med J. 1980;56:149–58.
    1. Brandsma D, Reijneveld JC, Taphoorn MJ, de Boer HC, Gebbink MF, Ulfman LH, et al. Vascular cell adhesion molecule-1 is a key adhesion molecule in melanoma cell adhesion to the leptomeninges. Lab Invest. 2002;82:1493–502.
    1. Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, et al. CSF protein profiling using Multiplex Immuno-assay: A potenteoal new diagnostic tool for leptomeningeal metastases. J Neurol. 2006;253:1177–84.
    1. Braen AP, Perron J, Tellier P, Catala AR, Kolaitis G, Geng W. A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys. Int J Toxicol. 2010;29:259–67.
    1. Brastianos PK, Brastanios HC, Hsu W, Sciubba DM, Kosztowski T, Tyler BM, et al. The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. J Neurooncol. 2012;106:81–8.
    1. Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, et al. Central nervous system cancers: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:644–90.
    1. Brem SS, Bierman PJ, Brem H, Buiowski N, Chamberlain MC, Chiocca EA, et al. National Comprehensive Cancer Network, Central nervous system. J Natl Compr Canc Netw. 2011;9:352–400.
    1. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon, Reiman R, et al. Intrathecal 131 I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res. 1996;2:963–72.
    1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–83.
    1. Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: A quantitative autoradiographic study. J Natl Cancer Inst. 1988;80:1211–6.
    1. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol. 1983;1:313–7.
    1. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology. 1990;40:435–8.
    1. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology. 1991;41:1765–9.
    1. Chamberlain MC, Dirr L. Involved-field radiotherapy and intra-Ommaya methotrexate/cytarabine in patients with AIDS-related lymphomatous meningitis. J Clin Oncol. 1993;11:1978–84.
    1. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol. 1993;50:261–4.
    1. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46:1674–7.
    1. Chamberlain M, Kormanik P. Leptomeningeal metastases due to melanoma. Int J Oncol. 1996;9:505–10.
    1. Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54:1364–8.
    1. Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: Predictors of response to combined modality therapy. J Neurooncol. 1997;35:55–64.
    1. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol. 1998;38:135–40.
    1. Chamberlain M. Leptomeningeal metastases: A review of evaluation and treatment. J Neurooncol. 1998;37:271–84.
    1. Chamberlain MC. Cytologically negative carcinomatous meningitis: Usefulness of CSF biochemical markers. Neurology. 1998;50:1173–5.
    1. Chamberlain MC, Kormanik P. Carcinomatous meningitis secondary to nonsmall cell lung cancer: Combined modality therapy. Arch Neurol. 1998;55:506–12.
    1. Chamberlain MC, Kormanik P, Jaeckle KA, Glantz M. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1999;52:216–7.
    1. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro-Oncology. 2001;3:42–5.
    1. Chamberlain MC. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2001;56:425–6.
    1. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94:2675–80.
    1. Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery. 2003;52:324–9.
    1. Chamberlain MC. Neoplastic meningitis: Deciding who to treat. Expert Rev Neurother. 2004;4:89–96.
    1. Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy: Prognostic significance. Neurology. 2004;63:2159–61.
    1. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106:2021–7.
    1. Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13:967–77.
    1. Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol. 2009;66:74–8.
    1. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: Detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 2009;36:S35–45.
    1. Chamberlain MC, Johnston SK. Neoplastic meningitis: Survival as a function of cerebrospinal fluid cytology. Cancer. 2009;115:1941–6.
    1. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010;22:627–35.
    1. Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: A retrospective case series. J Neurooncol. 2012;109:143–8.
    1. Chamberlain MC. Neuraxis imaging in leptomeningeal metastasis: A retrospective case series. CNS Tumors 2046. J Clin Oncol. 2012;30 (abstr 2046)
    1. Champagne MA, Silver HK. Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma. J Natl Cancer Inst. 1992;84:1203–4.
    1. Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep. 2003;5:24–8.
    1. Chen YM, Chen MC, Tsai CM, Perng RP. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis: A case report. Lung Cancer. 2003;40:99–101.
    1. Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, et al. Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol. 2006;76:85–92.
    1. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol. 2006;3:50–7.
    1. Chuang TY, Yu CJ, Shih JY, Yang PC, Kuo SH. Cytologically proven meningeal carcinomatosis in patients with lung cancer: Clinical observation of 34 cases. J Formos Med Assoc. 2008;107:851–6.
    1. Clamon G, Boebbeling B. Meningeal carcinomatosis from breast cancer: Spinal vs brain involvement. Breast Cancer Res Treat. 1987;9:213–7.
    1. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99:283–6.
    1. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74:1449–54.
    1. Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, et al. Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol. 2009;95:421–6.
    1. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using (131) I-radiolabelled monoclonal antibodies, results of responses and long term follow-up in 40 patients. J Neurooncol. 1998;38:225–32.
    1. Cokgor I, Akabani G, Friedman HS, Friedman AH, Zatusky MR, Zehngebot LM, et al. Long term response in a patient with neoplastic meningitis secondary to melnoma treated with (131) I-radiolabeled ant chondroitin proteoglycan sulfate Mel-14 F(ab’) (2): A case study. Cancer. 2001;91:1809–13.
    1. Cokgor I, Friedman AH, Friedman HS. Current options for the treatment of neoplastic meningitis. J Neurooncol. 2002;60:79–88.
    1. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003;97:3053–60.
    1. Corsini E, Bernardi G, Gaviani P, Silvani A, de Grazia U, Ciusani E, et al. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med. 2009;47:874–9.
    1. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001;12:353–6.
    1. D’Angio GJ, French LA, Stadlan EM, Kieffer SA. Intrathecal radioisotopes for the treatment of brain tumors. Clin Neurosurg. 1968;15:288–300.
    1. DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fiks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24:798–805.
    1. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998;38:245–52.
    1. de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, et al. Meningeal carcinomatosis in breast cancer: Prognostic factors and outcome. J Neurooncol. 2011;104:565–72.
    1. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol. 2010;100:443–7.
    1. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics. 2005;4:1341–9.
    1. Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: Response to high-dose erlotinib. J Clin Oncol. 2009;27:e31–2.
    1. Dicuonzo F, Salvati A, Palma M, Lefons V, Lasalandra G, De Leonardis F, et al. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: Conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol. 2009;24:1013–8.
    1. Dietemann JL, Correia Bernardo R, Bogorin A, Abu Eid M, Koob M, Nogueira T, et al. Normal and abnormal meningeal enhancement: MRI features. J Radiol. 2005;86:1659–83.
    1. Dinndorf PA, Bleyer WA. Management of infectious complications of intraventricular reservoirs in cancer patientsq: Low incidence and successful treatment without reservoir removal. Cancer Drug Deliv. 1987;4:105–17.
    1. Doge H, Hliscs R. Intrathecal therapy with 198Au-colloid for meningosis prophylaxis. Eur J Nucl Med. 1984;9:125–8.
    1. Donehower R, Karp J, Burke P. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep. 1986;70:1059–65.
    1. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, Veronese L, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases 8548. J Clin Oncol. 2011;29(Suppl) abstr 8548.
    1. Dux R, Kindler-Röhrborn A, Annas M, Faustmann P, Lennartz K, Zimmerman CW. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci. 1994;121:74–8.
    1. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85:223–7.
    1. Elliott JP, Keles GE, Waite M, Temkin N, Berger MS. Ventricular entry during resection of malignant gliomas: Effect on intracranial cerebrospinal fluid tumor dissemination. J Neurosurg. 1994;80:834–9.
    1. Esteva FJ, Soh LT, Holmes FA, Plunket W, Meyers CA, Forman AD, et al. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol. 2000;46:382–6.
    1. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet. 2012;379:1893–901.
    1. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol. 2009;20:792–5.
    1. Fishman RA. Cerebrospinal fluid in diseases of the nervous system. 2nd ed. Philadelphia: W.B. Saunders Company; 1992.
    1. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, et al. Meningeal carcinomatosis in patients with breast carcinoma.Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996;77:1315–23.
    1. Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer. 2001;84:1453–9.
    1. Frick J, Ritch PS, Hansen RM, Anderson T. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol. 1984;2:365–8.
    1. Fulton DS, Levin VA, Gutin PH, Edwards MS, Seager ML, Stewart J, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol. 1982;8:285–91.
    1. Gallego Perez-Larraya J, Palma JA, Carmona-Iragui M, Fernandez-Torron R, Irimia P, Rodrıguez-Otero P, et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactic ally to patients with non- Hodgkin's lymphoma. J Neurooncol. 2010;103:603–9.
    1. Gani C, Müller AC, Eckert F. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis form solid tumors. Strahlenther Oncol. 2012;188:148–53.
    1. Gaucher AS, Pez E, Boutonnat J, Bourre JC, Pelleter L, Payan R, et al. Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: Validation of CA 15-3 measurement in cerebrospinal fluid. Ann Biol Clin. 2007;65:653–8.
    1. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010;21:2183–7.
    1. Geldof AA. Models for cancer skeletal metastasis: A reappraisal of Batson's plexus. Anticancer Res. 1997;17:1535–9.
    1. Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003;65:167–72.
    1. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 1995;75:2919–31.
    1. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results. Cancer. 1998;82:733–9.
    1. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561–7.
    1. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–402.
    1. Glantz MJ, LaFollette S, Jaeckle K. Randomized trial of a slow- release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.
    1. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116:1947–52.
    1. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology. 1979;29:1369–75.
    1. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5:443–52.
    1. Gonzalez-Vitale JC, Garcia-Bunuel R. Meningeal carcinomatosis. Cancer. 1976;37:2906–11.
    1. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994;51:457–61.
    1. Grewal J, Saria MG, Kesari S. Novel approaches to treating leptomeningeal metastases. J Neurooncol. 2012;106:225–34.
    1. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodony AI, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13:1364–9.
    1. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic evaluation using 111indium-DTPA ventriculography. Am J Med. 1982;73:641–7.
    1. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis, Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11:561–9.
    1. Groves MD. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2006;66:1609–10.
    1. Groves MD, Glantz MJ, Chamberlain MC. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008;10:1010–8.
    1. Groves MD. Advances in treating leptomeningeal metastases, Educational Book. Alexandria, Virginia: American Society of Clinical Oncology; 2008. pp. 50–7.
    1. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, et al. Biomarkers of disease: Cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009;94:229–34.
    1. Groves MD. New strategies in the management of leptomeningeal metastases. Arch Neurol. 2010;67:305–12.
    1. Groves MD. Leptomeningeal disease. Neurosurg Clin North Am. 2011;22:67–78.
    1. Groves MD, DeGroot J, Tremont I, Forman A, Kang S, Pei BL, et al. A pilot study of systemically administered bevacizumab with neoplastic meningitis NM: Imaging, clinical, CSF and biomarker outcomes. Neuro Oncol (OT-02) 2011;13:iii85–91.
    1. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Philips PC, Friedman HS, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: A Pediatric Brain Tumor Consortium Study (PBTC-004) Clin Cancer Res. 2006;12:1540–6.
    1. Gütling E, Landis T, Kleihues P. Akinetic mutism in bilateral necrotizing leucoencephalopathy after radiation and chemotherapy: Electrophysiological and autopsy findings. J Neurol. 1992;239:125–8.
    1. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J Neurosurg. 1992;76:1–12.
    1. Hammerer V, Pauli G, Quoix E. Retrospective study of a series of 26 carcinomatous meningitis secondary to lung cancer. Bull Cancer. 2005;92:989–94.
    1. Hansen K, Gjerris F, Sorensen PS. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien) 1987;86:93–7.
    1. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. J Neurooncol. 2008;10:1010–8.
    1. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer. 2006;53:387–90.
    1. Hata A, Katakami N, Kaji R, Fujita S, Imai Y. Erlotinib for whole-brain-radiotherapy-refractory leptomeningeal metastases after gefitinib failure in a lung adenocarcinoma patient. J Thorac Oncol. 2012;7:770–1.
    1. Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol. 1998;38:233–9.
    1. Herrlinger U, Fösrschier H, Küker W, Meyermann R, Bamberg M, Dichgans J, et al. Leptomeningeal metastasis: Survival and prognosis in 155 patients. J Neurol Sci. 2004;223:167–78.
    1. Hiesiger EM, Picco-Del Bo A, Lipschutz LE, Basler GA, Thaler HT, Posner JB, et al. Experimental meningeal carcino-matosis selectively depresses local cerebral glucose utilization in rat brain. Neurology. 1989;39:90–5.
    1. Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, et al. Neurological complications after intrathecal liposomal cytarabine application in patients after allogenic hematopoietic stem cell transplantation. Ann Hematol. 2008;87:1009–12.
    1. Hisanaga M, Kawai S, Maekawa M, Hattori Y, Kotoh K. Neoplastic aneurysms due to cerebral metastasis of choriocarcinoma.Report of two cases. Neurol Med Chir (Tokyo) 1988;28:398–403.
    1. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655–62.
    1. Hoang-Xuan K, Napolitano M, Cornu P, Delattre JY. Metastases cerebrales et leptomeningees des cancers solides (French) Encyclopédie Medico Chirurgicale (Elsevier, Paris), Neurologie. 1999 17-225-A-210.
    1. Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B. Intrathecal trastuzumab: Dose matters. Acta Oncol. 2012;51:955–6.
    1. Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214–8.
    1. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a non-small cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006;24:4517–20.
    1. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001;84:157–63.
    1. Jaeckle KA. Neoplastic meningitis from systemic malignancies: Diagnosis, prognosis, and treatment. Semin Oncol. 2006;33:312–23.
    1. Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in patients with breast aggressive disease variant. Cancer. 1994;74:3135–41.
    1. Jiménez Mateos A, Cabrera Naranjo F, González Hernández A, Fabre Pi O, Díaz Nicolás S, López Fernández JC. Neoplastic meningitis. Review of a clinical series. Neurologia. 2011;26:227–32.
    1. Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH, et al. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg. 1989;70:240–8.
    1. Kanaji N, Bandoh S, Nagamura N, Kushida Y, Haba R, Ishida T. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Internal Med. 2007;46:1651–5.
    1. Kang SJ, Kim KS, Ha YS, Huh SY, Lee JH, Kim JK, et al. Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis. J Clin Neurol. 2010;6:33–7.
    1. Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, et al. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9:225–9.
    1. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4:1415–9.
    1. Kemshead JT, Papanastassiou V, Coakham HB, Pizer BL. Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer. 1992;28:511–3.
    1. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003;21:25–66.
    1. Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11:2186–93.
    1. Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol. 2003;33:608–12.
    1. Kim KH, Im SA, Keam B. Clinical outcomes of central nervous system metastases from breast cancer: Differences in survival depending on systemic treatment. J Neurooncol. 2012;106:303–13.
    1. Klein P, Haley EC, Wooten GF, Van den Berg SR. Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol. 1989;46:1149–52.
    1. Koch D. Spinal metastases of cerebral glioma.Case report. Neurosurg Rev. 1996;19:201–3.
    1. Kokkoris CP. Leptomeningeal carcinomatosis.How does cancer reach the pia-arachnoid? Cancer. 1983;51:154–60.
    1. Kramer K, Cheung NK, Humm JL, Dantis E, Finn R, Yeh SJ, et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131) I- 3F8. Med Pediatr Oncol. 2000;35:716–8.
    1. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101:810–6.
    1. Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991;115:507–10.
    1. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study. J Surg Oncol. 1991;48:28–33.
    1. Larson SM, Schall GL, Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med. 1971;12:555–7.
    1. Lashfford LS, Davies AG, Richardson RB, Bourne SP, Bullimore JA, Eckert H, et al. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer. 1988;61:857–68.
    1. Laske DW, Muraszko KM, Oldfield EH, DeVroom HL, Sung C, Dedrick RL, et al. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery. 2007;41:1039–49.
    1. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol. 2006;78:255–60.
    1. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer. 2001;2:235.
    1. Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, et al. Leptomeningeal metastases from breast cancer: Intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treatment. 2011;129:809–17.
    1. Le Rhun E, Taillibert S, Zairi F, Devos P, Pierret MF, Dubois F, et al. Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: A case-control study. J Neurooncol. 2011;105:309–15.
    1. Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M. Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol. 1989;23:301–7.
    1. Liaw CC, Ng KT, Huang JS, Wang CH, Kiu MC, Lai GM, et al. Meningeal carcinomatosis from solid tumors: Clinical analysis of 42 cases. J Formos Med Assoc. 1992;91:299–303.
    1. Lin M, Chen ZQ, Bao Y, Li Q, Du ZG, Xu ZD, et al. Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis. Zhonghua Bing Li Xue Za Zhi. 2010;39:372–6.
    1. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer. 2008;113:2638–45.
    1. Lin NU. Concordance of HER2 in primary tumor and leptomeningeal metastases: Now what.? Breast Cancer Research Treat. 2010;123:129–31.
    1. Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: A retrospective, case-controlled study. J Neurosurg. 2011;115:730–6.
    1. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA. Cytokine responses to intraventricular injection of interleu-kin 2 into patients with leptomeningeal carcinomatosis: Rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein) Cancer Res. 1992;52:1123–8.
    1. Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis.Clinical manifestations. Arch Neurol. 1974;30:138–43.
    1. MacDonald D, Cascino T, Schold SJ, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.
    1. Machado M, Salcman M, Kaplan RS, Montgomery E. Expanded role of the cerebrospinal fluid reservoir in neurooncology: Indications, causes of revision, and complications. Neurosurgery. 1985;17:600–3.
    1. Madow L, Alpers BJ. Encephalitic form of metastatic carcinoma. AMA Arch Neurol Psychiatry. 1951;65:161–73.
    1. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label phase 2 trial. Lancet Oncol. 2012;13:459–65.
    1. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1998;50:438–44.
    1. Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011;67:1465–9.
    1. Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, et al. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast. 2011;20:478–80.
    1. Mellett LB. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep. 1977;61:527–31.
    1. Metz O, Stoll W, Plenert W. Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia. Cancer. 1982;49:224–8.
    1. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008;19:1978–80.
    1. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol. 1989;7:1701–9.
    1. Mittl RL, Jr, Yousem DM. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. Am J Neuroradiol. 1994;15:633–8.
    1. Morra E, Lazzarino M, Brusamolino E, Pagnucco G, Castagnola C, Bernasconi P, et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia.Clinical results in 46 patients. Cancer. 1993;72:439–45.
    1. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7:382–5.
    1. Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990;62:637–42.
    1. Moseley RP, Benjamin JC, Ashpole RD, Sullivan NM, Bullimore JA, Coakham HB, et al. Carcinomatous meningitis: Antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry. 1991;54:260–5.
    1. Moser AM, Adamson PC, Gillespie AJ, Poplack DG, Balis FM. Intraventricular Concentration times time (CxT) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer. 1999;85:511–6.
    1. Myklebust AT, Godal A, Fodstad O. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Res. 1994;54:2146–50.
    1. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10:R20.
    1. Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: A potentially preventable complication. J Neurooncol. 1997;32:215–23.
    1. Novak LJ. Radiotherapy of the central nervous system in acute leukemia. Am J Pediatr Hematol Oncol. 1989;11:87–92.
    1. Obbens EA, Leavens ME, Beal JW, Lee YY. Ommaya reservoirs in 387 cancer patients: A 15-year experience. Neurology. 1985;35:1274–8.
    1. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: A retrospective analysis. J Cancer Res Clin Oncol. 2010;136:1729–35.
    1. Ojeda VJ. Necrotising leucoencephalopathy associated with intrathecal/intraventricular methotrexate therapy. Med J Aust. 1982;2:289–93.
    1. Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat. 2011;127:841–4.
    1. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer.A clinical and pathologic study. Arch Neurol. 1974;30:122–37.
    1. Omuro AM, Kris MG, Miller VA, Franchesci E, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005;103:2344–8.
    1. Orphanos G, Ardavanis A. Leptomeningeal metastases from prostate cancer: An emerging clinical conundrum. Clin Exp Metastasis. 2010;27:19–23.
    1. Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U. Neurological complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol. 2010;103:635–40.
    1. Ozdogan M, Samur M, Bozcuk HS, Sagtas E, Yildiz M, Artac M, et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: A case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol. 2003;33:229–31.
    1. Pace P, Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol. 2006;60:528–34.
    1. Park IH, Kwon Y, Ro JY, Lee KS, Ro J. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res Treat. 2010;123:125–8.
    1. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 2012;76:387–92.
    1. Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2:752–60.
    1. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–51.
    1. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2349–51.
    1. Petit T, Dufour P, Korganov AS, Maloisel F, Oberling F. Continuous intrathecal perfusion of methotrexate for carcinomatous meningitis with pharmacokinetic studies: Two case studies. Clin Oncol. 1977;9:189–90.
    1. Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases-treatment results in 98 consecutive patients. Israel J Med Sci. 1988;24:611–8.
    1. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 2006;7:778–80.
    1. Poplack D, Bleyer WA, Horowitz M. Pharmacology of antineoplastic agents in cerebrospinal fluid. New York: Plenum Press; 1980.
    1. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.
    1. Posner JB. Leptomeningeal metastases in Neurologic Complications of Cancer. Philadelphia: F.A. Davis Company; 1995. pp. 143–71.
    1. Price R, Jamieson P. The central nervous system in chidhood leukemia.Subacute leukoencephalopathy. Cancer. 1975;35:306–18.
    1. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.
    1. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32.
    1. Regierer AC, Stroux A, Kühnardt D, Dieing A, Lehenbauer-Dehm S, Flath B, et al. Contrast-enhancing meningeal lesions are associated with onger survival in breast cancer related leptomeningeal metastasis. Breast Care (Basel) 2008;3:118–23.
    1. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest. 2003;33:76–81.
    1. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2005;65:1120–2.
    1. Renbarger J, Aleksic A, McGuffey L, Dauser R, Berg S, Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2004;53:39–42.
    1. Robins HI, Liu G, Hayes L, Mehta M. Trastuzumab for breast cancer-related carcinomatous meningitis. Clinical Breast Cancer. 2002;2:316.
    1. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med. 2011;365:2439–41.
    1. Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol. 2004;6:63–4.
    1. Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: Findings on diffusion-weighted imaging and correlation with clinical outcome. Am J Neuroradiol. 2004;25:1688–95.
    1. Römpp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, et al. Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nano LC-FTICR MS. Proteomics. 2007;7:474–81.
    1. Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, et al. Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 1982;61:45–53.
    1. Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis: The role of multimodality treatment. J Neurooncol. 2007;84:57–62.
    1. Sakai M, Ishikawa S, Ito H, Ozawa Y, Yamamoto T, Onizuka M, et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol. 2006;11:243–5.
    1. Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: Sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphasis Tumor Immunol. 1993;13:49–54.
    1. Sause WT, Crowley J, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases: A Southwest Oncology Group study. J Neurooncol. 1988;6:107–12.
    1. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42:1044–56.
    1. Schumacher M, Orszagh M. Imaging techniques in neoplastic meningiosis. J Neurooncol. 1998;38:111–20.
    1. Segura PP, Gil M, Balana C, Chacon I, Langa JM, Martin M, et al. Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. J Neurooncol. 2012;109:137–42.
    1. Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.
    1. Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep. 1977;61:733–43.
    1. Shapiro WR, Johanson CE, Boogerd W. Treatment modalities for leptomeningeal metastases. Semin Oncol. 2009;36:S46–54.
    1. Shi Q, Pu CQ, Huang XS, Tian CL, Cao XT. Optimal cut-off values for tumor markers in cerebrospinal fluid with ROC curve analysis. Front Biosci (Elite Ed) 2011;3:1259–64.
    1. Shigekawa T, Takeuchi H, Misumi M, Matsuura K, Sano H, Fujiuchi N, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: A case report. Breast Cancer. 2009;16:88–92.
    1. Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol. 2011;6:1215–20.
    1. Siddiqui F, Marr L, Weissman DE. Neoplastic meningitis # 135. J Palliat Med. 2009;12:88–9.
    1. Siegal T, Mildworf B, Stein D, Melamed E. Leptomeningeal metastases: Reduction in regional cerebral blood flow and cognitive impairment. Ann Neurol. 1985;17:100–2.
    1. Siegal T, Pfeffer MR, Steiner I. Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery. 1988;22:97–100.
    1. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: Analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44:1463–9.
    1. Siegal T. Leptomeningeal metastases: Rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol. 1998;38:151–7.
    1. Siegal T. Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep. 2003;5:41–9.
    1. Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report. J Med Case Rep. 2012;6:131.
    1. Singh SK, Leeds NE, Ginsberg LE. Imaging of leptomeningeal metastases: Comparison of three sequences. Am J Neuroradiol. 2002;23:817–21.
    1. Slavc I, Schuller E, Falger J, Günes M, Pillwein K, Czech T, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11): Experience in 26 children with disseminated malignant brain tumors. J Neurooncol. 2003;64:239–47.
    1. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1:546–51.
    1. So T, Inoue M, Chikaishi Y, Nose N, Sugio k, Yasumoto K. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: Report of two cases. Surg Today. 2009;39:598–602.
    1. Soffietti R, Akerley W, Jensen RL, Bischoff J, Regierer AC. The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. Semin Oncol. 2009;36:S55–68.
    1. Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lässig D, et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2- overexpressing metastatic breast cancer. Oncol Rep. 2006;15:1373–7.
    1. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18:23–8.
    1. Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Hermann KA, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER-2 overexpressing metastatic breast cancer: A case report. Anticancer Drugs. 2008;19:832–6.
    1. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Mulgg A, Kiechl S, et al. Vascular endothelial growth factor in CSF: A biological marker for carcinomatous meningitis. Neurology. 2000;54:1670–6.
    1. Strazielle N, Khuth ST, Ghersi-Egea JF. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev. 2004;56:1717–40.
    1. Strong JM, Collins JM, Lester C, Poplack DG. Pharmacokinetics of intraventricular and intravenous N, N’, N’-triethylenethi-ophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 1986;46:6101–4.
    1. Sudo J, Hnmuora Y, Kurimoto F, Komagata H, Sakai H, Yoneda S. Meningela carcinomatosis in patients with lung cancer. Nihon Kokyuki Gakkai Zasshi. 2006;44:795–9.
    1. Sundaresan N, Suite ND. Optimal use of the Ommaya reservoir in clinical oncology. Oncology (Huntingt) 1989;3:15–22.
    1. Sze G, Soletsky S, Bronen R, Krol G. MR Imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am J Roentgenol. 1989;153:1039–49.
    1. Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: A case report. Clin Breast Cancer. 2006;7:164–6.
    1. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: A review. J Neurooncol. 2005;75:85–99.
    1. Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J. 2007;48:e46–9.
    1. Tetsumoto S, Osa A, Kijima T, Minami T, Hirata H, Takahashi R, et al. Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. 2012;17:155–9.
    1. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol. 1981;38:696–9.
    1. Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, et al. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature. Lung Cancer. 2012;77:464–8.
    1. Trump DL, Grossman SA, Thompson G, Murray K. CSF infections complicating the management of neoplastic meningitis.Clinical features and results of therapy. Arch Intern Med. 1982;142:583–6.
    1. Tufekci O, Yilmaz S, Karapinar TH, Gozmen S, Cakmakci H, Hiz S, et al. A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2011;28:517–22.
    1. Turpin A, Pannier D, Zairi F, Cazin JL, Bonneterre J, Le Rhun E. Interest of a second line treatment with intrathecal thiotepa in the treatment of breast cancer leptomeningeal metastases (French) Journées de Neurologie de Langue Française, Nice. 2012
    1. van de Lagerijt B, Gijtenbeek JM, de Reus HP, Sweep FC, Geurts-Moespot A, Hendricks JC, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology. 2006;67:114–9.
    1. van der Ree TC, Dippel DW, Avezaat CJ, Sillevis Smitt PA, Vecht CJ, van den Bent MJ. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry. 1999;66:225–7.
    1. van Zanten AP, Twijnstra A, Ongerboer de Visser BW, van Heerde P, Hart AA, Nooyen WJ. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry. 1991;54:119–23.
    1. Wagner M, Besse B, Balleyguier C, Soria JC. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol. 2008;3:677–9.
    1. Waki F, Masashi A, Takashima A, Yonemori K, Nokihara H, Miyake M, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 2009;93:205–12.
    1. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer. 1982;49:759–72.
    1. Wasserstrom WR. Leptomeningeal metastases. In: Wiley RG, editor. Neurological Complications of Cancer. New York: Marcel Dekker; 1995. pp. 45–71.
    1. Waters KD. Leucoencephalopathy in patients on methotrexate. Lancet. 1978;2:46.
    1. Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: Retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011;21:530–4.
    1. Wen PY, Macdonald DR, Reardon DA, Cloughesy A, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.
    1. Weston CL, Glantz MJ, Connor JR. Detection of cancer cells in the cerebrospinal fluid: Current methods and future directions. Fluids Barriers CNS. 2011;8:14.
    1. Witham TF, Fukui MB, Meltzer CC, Burns R, Kondziolka D, Bozik ME. Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer. 1999;86:1347–53.
    1. Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 2009;65:80–4.
    1. Youle RJ. Immunotoxins for central nervous system malignancy. Semin Cancer Biol. 1996;7:65–70.
    1. Zairi F, Kotecki N, Rodrigues I, Baranzelli MC, Andre C, Dubois F, et al. Prospective follow-up of a cohort of 112 patients with leptomeningeal metastases of breast cancer recruited from 2007 to 2011: Prognostics factors.General Poster Session, Central Nervous System, abstract 2070, American Society of Clinical Oncology, Annual Meeting, 2012; June, Chicago, IL. J Clin Oncol. 2012:30.
    1. Zhuang Y, Fraga CH, Hubbard KE, Hagedomm N, Panetta JC, Waters CM, et al. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res. 2006;66:11305–13.
    1. Zimm S, Collins JM, Miser J, Chatterji D, Poplack D. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther. 1984;35:826–30.
    1. Zovickian J, Youle RJ. Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. J Neurosurg. 1988;68:767–74.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren